Feline Chronic Kidney Disease: A Practical Management Guide

Feline Chronic Kidney Disease: A Practical Management Guide

Chronic kidney disease (CKD) is one of the most prevalent conditions in cats, affecting an estimated 30–40% of cats over 10 years of age. This guide summarises current evidence-based recommendations for diagnosis, staging, and long-term management in general practice.

Epidemiology and Clinical Significance

CKD carries a significant prognostic burden in cats. A 2024 systematic review (Journal of Veterinary Internal Medicine, PMID: 41482870) confirmed that early-stage CKD (IRIS Stages 1–2) can be managed effectively for years with appropriate dietary and medical intervention, while advanced disease (Stage 4) carries a median survival of only weeks to months.

IRIS Staging — The Foundation of Management

The International Renal Interest Society (IRIS) staging system guides management decisions based on serum creatinine and SDMA levels, with sub-staging based on proteinuria (UPC ratio) and blood pressure.

Important: SDMA rises earlier than creatinine (detects ~40% loss of GFR vs ~75% for creatinine), making it a valuable early marker.

Dietary Management — The Cornerstone of Treatment

Renal diets (reduced protein, phosphorus, and sodium; supplemented omega-3 fatty acids) remain the single most evidence-based intervention for slowing CKD progression in cats.

Key dietary targets:

• Phosphorus restriction is critical from Stage 2 onward. Dietary phosphorus should be < 0.5% DM (dry matter basis).
• Protein restriction reduces nitrogenous waste load but must be balanced against the risk of muscle wasting — a major concern in older cats.
• Omega-3 fatty acids (EPA/DHA) have anti-inflammatory and renoprotective effects.

> Reference: Sparkes et al. (2016). Journal of Feline Medicine and Surgery. PMID: 26780857

Phosphate Binders

When dietary phosphorus restriction alone is insufficient to achieve target serum phosphorus, add a phosphate binder:

• Aluminium hydroxide (30–90 mg/kg/day divided with meals)
• Lanthanum carbonate — effective with fewer systemic concerns
• Calcium carbonate — avoid if hypercalcaemia is present

Managing Proteinuria

Proteinuria (UPC > 0.4 in cats) is an independent predictor of faster CKD progression and increased mortality.

Treatment:

• Benazepril (0.5–1 mg/kg PO q24h) — most evidence-based ACEi in cats with proteinuric CKD
• Telmisartan (1 mg/kg PO q24h) — angiotensin receptor blocker, effective for proteinuria reduction in cats

> Note: Never combine ACE inhibitors with NSAIDs in CKD patients — this combination reduces glomerular filtration pressure and can precipitate acute-on-chronic kidney injury.

Blood Pressure Management

Systolic hypertension (> 160 mmHg) causes target organ damage (retinal detachment, left ventricular hypertrophy, neurological signs) and accelerates renal deterioration.

First-line antihypertensive in cats:

• Amlodipine 0.625–1.25 mg/cat PO q24h — most effective and well-tolerated antihypertensive in cats
• If inadequate response: add telmisartan

Anaemia Management

Non-regenerative anaemia is common in advanced CKD (IRIS Stage 3–4) due to reduced erythropoietin production.

Options:

• Darbepoetin alfa (1 mcg/kg SC q7 days) — monitor PCV weekly initially
• Iron supplementation — ensure iron stores are adequate before ESA therapy

> Reference: PMID: 38587872

Monitoring Protocols

At each visit, assess: Body weight, BCS/MCS, hydration, blood pressure, serum creatinine, BUN, phosphorus, potassium, PCV, UPC.

Quality of Life Considerations

Nausea and reduced appetite are major quality-of-life concerns in CKD cats.

• Maropitant (1–2 mg/kg PO q24h) reduces nausea effectively
• Mirtazapine (1.875 mg/cat transdermal q48h) improves appetite significantly
• Subcutaneous fluid therapy at home (40–60 mL/cat/day) substantially improves wellbeing in Stage 3–4 cats

Using PetChart for CKD Management

PetChart enables structured CKD monitoring workflows:

• IRIS stage calculated and displayed automatically from lab values
• Automated reminders based on IRIS stage monitoring protocols
• Drug interaction alerts flag NSAID use in CKD patients at the point of prescribing
• Trend graphs track creatinine, SDMA, and UPC over time

---

Based on IRIS CKD Guidelines and peer-reviewed literature. PMIDs: 41482870, 38587872, 40235283, 26780857. Individual patient management should always be guided by clinical assessment and current evidence.